Author: Sara Spurlock, DDS
Founding Clinical Partner to OraPath
How to use salivary diagnostics to inform clinical decisions — not replace them
Salivary diagnostics have changed the way we understand the oral microbiome. For the first time, clinicians can identify periodontal pathogens, assess microbial burden, evaluate inflammatory markers, and get a clearer biological picture of what’s driving oral disease in a specific patient. That’s genuinely powerful.
But like any diagnostic tool, the value is in how you use it.
One of the most common questions we hear: “If a pathogen shows up on the salivary test, shouldn’t we prescribe antibiotics?”
Not necessarily.
A laboratory result identifies what’s present. It does not tell you whether that finding is driving active disease, whether the patient needs treatment, or what that treatment should be. That determination still requires a clinician — one who is integrating the test result with a full clinical examination, periodontal measurements, radiographic findings, patient symptoms, and a thorough understanding of risk factors.
The goal of salivary diagnostics was never to generate prescriptions. The goal is to help clinicians make better decisions. Those are two very different things.
Presence Is Not the Same as Disease
This principle isn’t unique to dentistry. It runs through all of medicine.
A patient can carry elevated cholesterol without having heart disease. A patient can have Staphylococcus on their skin without having an infection. A patient can test positive for HPV without developing cancer. In each case, the finding matters — but the finding alone doesn’t determine the treatment.
The oral cavity works the same way. It houses hundreds of bacterial species. Many organisms we classify as periodontal pathogens exist in the mouths of completely healthy individuals. Their presence in a salivary sample is meaningful data. It is not, by itself, a diagnosis.
Context is everything.
When we review salivary diagnostic results, we’re asking: Is there clinical inflammation? Is there bleeding on probing? Are pockets deepening? Is attachment loss occurring? Is bone loss progressing radiographically? Is the patient symptomatic? Do the microbial findings actually correlate with what we’re seeing chairside?
Only after working through those questions does antimicrobial therapy enter the conversation.
The Candida Example: What Are We Actually Treating?
Take elevated Candida on a salivary report. The reflexive response for some clinicians is to reach for Mycelex troches or another antifungal. But before that conversation happens, there’s a more important question to answer: what disease are we treating?
A salivary test detects Candida DNA. It does not diagnose oral candidiasis.
Before antifungals are even on the table, we want to know what’s happening clinically. Is the patient experiencing burning mouth, altered taste, angular cheilitis? Are there pseudomembranous lesions, erythematous candidiasis, denture stomatitis, mucosal sensitivity? Any observable findings consistent with fungal overgrowth?
We also want to understand the risk picture. Is the patient dealing with xerostomia, diabetes, immunosuppression? Have they been on antibiotics recently? Do they use inhaled corticosteroids or wear removable prosthetics?
If the tissues look healthy and the patient has no symptoms, prescribing an antifungal means treating a lab value — not a disease. In those cases, the better path is improving oral hygiene, reducing biofilm burden, addressing contributing risk factors, and supporting microbial balance through probiotic strategies before ever considering pharmaceutical intervention.
A Real Patient. A Real Decision.
Recently, we evaluated a patient preparing for a total knee replacement. Her orthopedic team wanted a thorough oral health assessment before surgery — a smart move given what we know about the relationship between oral pathogens and postoperative complications.
Her salivary report showed elevated Fusobacterium nucleatum, elevated Capnocytophaga species, mild Parvimonas micra, and low-level Candida. On paper, that reads like a concerning microbial profile. Some clinicians would look at those findings and immediately consider antimicrobial therapy.
But the clinical examination told a different story entirely.
She had minimal bleeding on probing, minimal inflammation, no deep periodontal pockets, no active attachment loss, and no radiographic evidence of progressive bone loss. Her periodontal status was stable. And critically, the pathogens most strongly linked to active destructive periodontal disease — Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Treponema denticola, Filifactor alocis, Prevotella intermedia — were absent or present at extremely low levels.
The salivary findings told us something real and useful: microbial complexity, biofilm maturation, a patient worth monitoring carefully. What they did not tell us was that this patient needed antibiotics.
Prescribing them anyway would have exposed her to medication risks — GI disruption, opportunistic infections, microbiome disruption — without providing any meaningful clinical benefit. Instead, treatment focused on professional biofilm disruption, enhanced oral hygiene instruction, and scheduled monitoring to track microbial trends over time.
That’s salivary diagnostics working the way they should.
When Antibiotics Are the Right Call
The flip side is equally important, because sometimes salivary diagnostics are exactly what tips the clinical decision toward treatment.
Consider a different patient — one presenting with generalized bleeding on probing, multiple pockets in the 6–8mm range, progressive bone loss, high inflammatory burden, and disease that hasn’t responded adequately to conventional therapy. Her salivary report shows high Aggregatibacter actinomycetemcomitans, elevated Porphyromonas gingivalis, elevated Tannerella forsythia and Treponema denticola, and elevated Filifactor alocis.
Now the microbial findings and the clinical picture are telling the same story. Active disease. Ongoing destruction. Pathogens strongly associated with progression. Mechanical therapy alone may not be enough.
In a case like this, adjunctive antimicrobial therapy is a reasonable, evidence-supported decision — not because bacteria were detected on a test, but because the full clinical picture supports it.
It’s also worth being clear about what antibiotics do and don’t do. They don’t remove calculus. They don’t address biofilm. They don’t cure periodontal disease. Mechanical disruption is always the foundation. But when significant pathogens are actively contributing to disease, targeted antimicrobial therapy can help reduce bacterial load and improve treatment outcomes. The distinction is that we’re treating disease — not reacting to a report.
Why This Matters Beyond the Individual Patient
Antibiotic stewardship is one of the most pressing issues in modern healthcare. Every unnecessary prescription contributes to resistance patterns that affect patients well beyond the one sitting in your chair. The risks of overprescribing are real: gastrointestinal consequences, allergic reactions, opportunistic infections, gut microbiome disruption, and a broader public health problem that dentistry has a responsibility to take seriously.
Salivary diagnostics should make us smarter prescribers — not more frequent ones.
The right question is never simply whether a pathogen is present. The right question is whether that pathogen is contributing to active disease that actually warrants treatment.
The Bigger Picture
Two patients can walk in with nearly identical salivary reports and need completely different treatment plans. One may need nothing beyond optimized home care and consistent maintenance. The other may need scaling and root planing, surgical intervention, or adjunctive antibiotics.
The difference isn’t in the lab report. It’s in the complete clinical picture.
Salivary diagnostics are most powerful when they’re used to enhance clinical judgment — adding biological depth to what the examination, the radiographs, and the patient’s history are already telling you. When that integration happens well, these tools become genuinely transformative. They help identify patients at increased risk before disease progresses, flag persistent microbial sources driving recurrence, reveal biofilm patterns that explain treatment resistance, and support more personalized, evidence-based care.
That’s the promise of this technology. Not that it replaces the clinician’s judgment. But that it makes that judgment sharper, more informed, and more defensible.
The test is a tool. The diagnosis still belongs to you.
OraPath salivary diagnostics are designed to be one part of a comprehensive clinical workup — giving clinicians deeper biological insight to support better patient care.